

## ‘Running on empty’


Damian Wild · Aikaterini Theodoraki ·  
Tom R. Kurzwinski · Jamshed Bomanji ·  
Jean Claude Reubi · Rehman Khan · Pierre Bouloux ·  
Bernard Khoo

Received: 11 February 2010 / Accepted: 12 March 2010 / Published online: 24 April 2010  
© Springer-Verlag 2010

A patient presented with spells of light-headedness, confusion and collapses, improving on eating. During a supervised fast, plasma glucose dropped to 1.7 mmol/l, with inappropriately high insulin, raised C-peptide and no sulphonylurea detectable, diagnostic of an insulinoma [1].

CT, MRI and abdominal ultrasound scanning failed to find any evidence of a lesion in the pancreas and all showed a liver lesion (a: black arrow). Somatostatin subtype 2 (sst<sub>2</sub>) receptor imaging with <sup>68</sup>Ga-DOTATATE PET/CT was normal (b). The white arrow shows the body of the pancreas in each panel.

Glucagon-like peptide-1 (GLP-1) receptor SPECT/CT was performed. This showed strong focal uptake posteriorly within the pancreatic body (c: white arrow). Notably, the liver lesion



D. Wild · J. Bomanji  
Institute of Nuclear Medicine,  
University College London Hospitals NHS Trust,  
London NW1 2BU, UK

A. Theodoraki · P. Bouloux · B. Khoo (✉)  
Department of Endocrinology,  
Royal Free Hampstead NHS Trust,  
Pond Street, London NW3 2QG, UK  
e-mail: b.khoo@ucl.ac.uk

T. R. Kurzwinski  
Centre for Endocrine Surgery,  
University College London Hospitals NHS Trust,  
London NW1 2PG, UK

J. C. Reubi  
Institute of Pathology,  
Division of Cell Biology and Experimental Cancer Research,  
University of Bern, Bern, Switzerland

R. Khan  
Department of Endocrinology, Basildon and Thurrock NHS Trust,  
Basildon, Essex SS16 5NL, UK

did not show any uptake. The pancreatic lesion was enucleated and the liver lesion was excised. Histopathology showed a well-differentiated insulinoma in the pancreas. The liver lesion proved to be a metastasis from a salivary gland-type lung tumour, previously resected in 2008. The insulinoma was found on autoradiography in vitro to express GLP-1 receptors but not sst<sub>2</sub> receptors.

GLP-1 is a gut hormone that stimulates insulin release from beta cells and represses glucagon release from alpha cells. <sup>111</sup>In-labelled exendin-4 is a GLP-1 analogue and can be used to image tissues that express GLP-1 receptors in high density [2–4]. In a prospective study, GLP-1 receptor imaging correctly located all six insulinomas preoperatively [2]. This new imaging modality may therefore be useful in locating small and occult tumours to guide surgery and to distinguish them from coincident lesions.

## References

1. Cryer PE, Axelrod L, Grossman AB, Heller SR, Montori VM, Seaquist ER, et al. Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab* 2009;94:709–28. doi:[jc.2008-1410](https://doi.org/10.1210/jc.2008-1410), [pii] [10.1210/jc.2008-1410](https://doi.org/10.1210/jc.2008-1410).
2. Christ E, Wild D, Forrer F, Brändle M, Sahli R, Clerici T, et al. Glucagon-like peptide-1 receptor imaging for localization of insulinomas. *J Clin Endocrinol Metab* 2009;94:4398–405. doi:[jc.2009-1082](https://doi.org/10.1210/jc.2009-1082), [pii] [10.1210/jc.2009-1082](https://doi.org/10.1210/jc.2009-1082).
3. Körner M, Stöckli M, Waser B, Reubi JC. GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. *J Nucl Med* 2007;48:736–43. doi:[48/5/736](https://doi.org/10.2967/jnumed.106.038679), [pii] [10.2967/jnumed.106.038679](https://doi.org/10.2967/jnumed.106.038679).
4. Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. *Eur J Nucl Med Mol Imaging* 2003;30:781–93. doi:[10.1007/s00259-003-1184-3](https://doi.org/10.1007/s00259-003-1184-3).